

2026-27 COVID-19 Vaccine Administration Protocol/Standing Order for Pharmacists

VACCINE PROTOCOL FOR PERSONS 12 THROUGH 64 YEARS OF AGE

This protocol/standing order is effective September 17, and shall remain in effect until September 16, 2027, or when rescinded by the Minnesota Department of Health's (MDH) State Epidemiologist and Medical Director or her designee, whichever occurs first. MDH retains the right to modify, rescind, or supplement this protocol/standing order as needed.

Condition for protocol/standing order

To reduce incidence of morbidity and mortality of COVID-19 disease, this protocol/standing order offers a mechanism to facilitate accessibility of COVID-19 vaccines by authorizing qualified health care professionals, as defined below, to administer 2026-27 COVID-19 vaccines to eligible individuals who meet the criteria established below by MDH.

This protocol/standing order is intended to supplement the authority that currently exists under Minnesota state and federal law for qualified health professionals to administer COVID-19 vaccines.

Authority

This non-patient specific protocol/standing order is issued by the MDH's State Epidemiologist and Medical Director in her official capacity and authorizes qualified health professionals, practicing in the State of Minnesota and in accordance with their respective scopes of practice, to assess eligibility and administer the most updated versions of the FDA-approved 2026-27 COVID-19 vaccine appropriate for age and health status as described below.

As defined in this protocol/standing order, qualified health care professionals are pharmacists who hold an active Minnesota license and are legally permitted to administer immunizations. Pharmacists may delegate the administration of vaccines to qualified pharmacy personnel (including nurses supporting pharmacists in administration of vaccines in pharmacy settings) in accordance with the laws and rules governing their scope of practice.

Policy

Participating pharmacists will implement this protocol/standing order for COVID-19 vaccination using the 2026-27 COVID-19 vaccine products for people 12 through 64 years of age consistent with the criteria and eligibility described below.

The indications in this protocol/standing order are based on recommendations from the American Academy of Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), American Academy of Family Physicians (AAFP), and the Infectious Diseases Society of America (IDSA).

Condition-specific criteria and prescribed actions

2026-27 COVID-19 VACCINE ADMINISTRATION PROTOCOL/STANDING ORDER FOR PHARMACISTS

Indications

Criteria	Prescribed action
Person is currently healthy and aged 12 through 64 years, and is one or more of the following: ▪ At high risk for severe COVID-19 due to an underlying medical condition*. ▪ Includes moderate to severe immune compromise (see below). ▪ A resident of long-term care facility or congregate setting. ▪ Has never been vaccinated for COVID-19. ▪ A person whose household contacts are at high risk for severe COVID-19. ▪ Pregnant (any trimester) or lactating. ▪ Healthcare personnel. ▪ A person who desires (or whose parent or guardian desires) protection from COVID-19.	Proceed to vaccinate.
Person with moderate to severe immunocompromise**.	Proceed to vaccinate using schedule for people with immunocompromising conditions. Counsel the individual and/or parent/guardian about: 1) The potential for reduced immune responses. 2) The need to continue to follow current guidance for COVID-19 prevention (visit COVID-19: Protect Yourself and Others (www.health.state.mn.us/diseases/coronavirus/prevention.html) for prevention strategies). Refer to primary care provider and/or specialist if additional doses may be indicated.
Person is under 3 years of age.	Do not vaccinate. Refer to primary care provider for vaccination.
Person is 3 through 11 years of age.	Do not vaccinate under this protocol. Refer to the <i>2026-27 COVID-19 Vaccine Administration Protocol/Standing Order for Pharmacists</i> for persons 3 through 11 years of age.

*Visit [American Academy of Pediatrics: Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026–2027: Technical Report \(https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2026-079046/208786/Recommendations-for-COVID-19-Vaccines-in-Infants\)](https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2026-079046/208786/Recommendations-for-COVID-19-Vaccines-in-Infants) and [CDC: Underlying Conditions and the Higher Risk for Severe COVID-19 \(www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html\)](https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html) for lists of high-risk underlying conditions or treatments. **Note these lists are not exhaustive.** Patients (or their parents or guardians) may self-attest to their underlying condition.

Visit [IDSA 2026 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients \(https://www.idsociety.org/practice-guideline/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/\)](https://www.idsociety.org/practice-guideline/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/) for a description of moderate and severe immunocompromising conditions and treatments. **Note this list is not exhaustive.

2026-27 COVID-19 VACCINE ADMINISTRATION PROTOCOL/STANDING ORDER FOR PHARMACISTS

Contraindications

Criteria: Allergies	Prescribed action
Person had a severe allergic reaction (e.g., anaphylaxis) to a previous dose of the same COVID-19 vaccine type or any of its components.	Do not vaccinate with the same COVID-19 vaccine type. May administer the alternate COVID-19 vaccine type. The mRNA COVID-19 vaccines (Moderna Spikevax and mNEXSPIKE and Pfizer-BioNTech Comirnaty) are one type of COVID-19 vaccine, and the protein subunit vaccine (Sanofi Nuvaxovid) is another type of COVID-19 vaccine.

Precautions

Criteria	Prescribed action
Person has a moderate to severe acute illness with or without fever (defined as temperature 100.4°F/38°C or higher).	Defer vaccination and refer to their primary care provider for assessment.
Person was diagnosed with non-severe allergy (e.g., urticaria beyond the injection site) to a component of a COVID-19 vaccine; or non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of a COVID-19 vaccine.	Defer vaccination and refer to their primary care provider to receive an assessment of their current health condition and assessment of individual benefits and risks.
Person has a history of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A).	Defer vaccination and refer to their primary care provider to receive an assessment of their current health condition and assessment of individual benefits and risks.
Person has a history of myocarditis or pericarditis within three weeks after a previous dose of any COVID-19 vaccine.	Defer vaccination and refer to their primary care provider to receive an assessment of their current health condition and assessment of individual benefits and risks.
Person had a delayed allergic reaction at the injection site (e.g., erythema, induration, pruritus at the injection site).	Proceed to vaccinate. Give vaccine in the opposite arm from where the previous dose was given if known.

Prescription

Give any of the following products using the same vaccine product to complete the initial series and according to the schedule below:

- 2026-27 Pfizer-BioNTech Comirnaty COVID-19 vaccine, gray label; 30 mcg, **0.3 mL**, intramuscular (IM)
- 2026-27 Moderna Spikevax COVID-19 vaccine, blue label; 50 mcg, **0.5 mL**, intramuscular (IM)
- 2026-27 Moderna mNEXSPIKE COVID-19 vaccine, teal label; 10 mcg, **0.2 mL**; intramuscular (IM)
- 2026-27 Sanofi (previously Novavax) Nuvaxovid COVID-19 vaccine, dark cyan label; 5 mcg, **0.5 mL**, intramuscular (IM)

12 through 64 years of age

Unvaccinated

- 12 through 18 years of age:
 - Give one dose of Moderna Spikevax, Moderna mNEXSPIKE, Pfizer-BioNTech Comirnaty, or Sanofi Nuvaxovid.

If previously vaccinated before 2026-27 vaccine

- 12 through 18 years of age:

2026-27 COVID-19 VACCINE ADMINISTRATION PROTOCOL/STANDING ORDER FOR PHARMACISTS

- Give one dose of Moderna Spikevax, Pfizer-BioNTech Comirnaty, or Sanofi Nuvaxovid at least 8 weeks after the most recent dose.
- Give one dose of Moderna mNEXSPIKE at least 12 weeks after the last dose was received.
- 19 through 64 years of age and vaccinated with:
 - One or more doses Moderna or Pfizer-BioNTech:
 - Give one dose 2026-27 Moderna Spikevax or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty vaccine at least 8 weeks following any previous COVID-19 vaccine dose.
 - Give one dose 2026-27 Moderna mNEXSPIKE vaccine at least 12 weeks after the most recent dose.
 - One dose Novavax:
 - Give one dose 2026-27 Sanofi Nuvaxovid 3-8 weeks after most recent dose. If more than 8 weeks after most recent dose, administer one dose 2026-27 Moderna Spikevax, Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty.
 - Give one dose 2026-27 Moderna mNEXSPIKE vaccine at least 12 weeks after the most recent dose.
 - Two or more doses Novavax:
 - Give one dose 2026-27 Moderna Spikevax or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty at least 8 weeks after the most recent dose.
 - Give one dose 2026-27 Moderna mNEXSPIKE vaccine at least 12 weeks after the most recent dose.
 - One or more doses Janssen:
 - Give one dose 2026-27 Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty.

For persons with immunocompromising conditions 12 through 64 years of age

Unvaccinated*

- Give four doses (three-dose initial series Moderna Spikevax or Moderna mNEXSPIKE at 0, 4 weeks, and at least 4 weeks after dose two, followed by one dose Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months later [minimum interval 2 months]).**

OR

- Give four doses (three-dose initial series Pfizer-BioNTech Comirnaty at 0, 3 weeks, and at least 4 weeks after dose two, followed by one dose Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months later [minimum interval 2 months]).**

OR

- Give three doses (two-dose initial series Sanofi Nuvaxovid at 0, 3 weeks, followed by one dose Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Novavax or Pfizer-BioNTech Comirnaty 6 months later [minimum interval 2 months]).**

Incomplete initial vaccination series

Previous vaccination with Moderna

- One dose Moderna: Give two doses Moderna Spikevax at least 4 weeks apart (administer dose one Moderna Spikevax 4 weeks after most recent dose), followed by one dose

2026-27 COVID-19 VACCINE ADMINISTRATION PROTOCOL/STANDING ORDER FOR PHARMACISTS

Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months later (minimum interval 2 months).**

- Two doses Moderna: Give one dose Moderna Spikevax at least 4 weeks after most recent dose, followed by one dose Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months later (minimum interval 2 months).**

Previous vaccination with Pfizer-BioNTech

- One dose Pfizer-BioNTech: Give two doses Pfizer-BioNTech Comirnaty at least 4 weeks apart (administer dose one Pfizer-BioNTech Comirnaty 3 weeks after most recent dose), followed by one dose Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer BioNTech Comirnaty 6 months later (minimum interval 2 months).**
- Two doses Pfizer-BioNTech: Give one dose Pfizer-BioNTech Comirnaty at least 4 weeks after most recent dose, followed by one dose Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months later (minimum interval 2 months).**

Previous vaccination with Novavax

- One dose NovavaxNovavax: Give one dose Sanofi NuvaxovidNovavax at least 3 weeks after most recent dose, followed by one dose Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months later (minimum interval 2 months).**

Completed initial three-dose vaccination series

- Three or more doses Moderna or three or more doses Pfizer BioNTech: Give two doses Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months apart (minimum interval 2 months). Administer dose one at least 8 weeks after the most recent dose.**
- Two or more doses Novavax: Give two doses Moderna Spikevax or Moderna mNEXSPIKE or Sanofi Nuvaxovid or Pfizer-BioNTech Comirnaty 6 months apart (minimum interval 2 months). Administer dose one at least 8 weeks after the most recent dose.**

*Use vaccine from the same manufacturer for all doses in the initial vaccination series. Either Moderna product (Spikevax or mNEXSPIKE) can be used unless otherwise specified.

**Additional doses of COVID-19 vaccine for moderately or severely immunocompromised: Based on shared clinical decision making and administered at least 2 months after the most recent dose.

Medical emergency or anaphylaxis

Vaccinators should be prepared to recognize and manage vaccine reactions and medical emergencies related to the administration of vaccines, including anaphylaxis. Follow your organization's pre-established protocol for anaphylaxis or refer to these suggested resources:

- [CDC: Preventing and Managing Adverse Reactions \(www.cdc.gov/vaccines/hcp/imz-best-practices/preventing-managing-adverse-reactions.html\)](https://www.cdc.gov/vaccines/hcp/imz-best-practices/preventing-managing-adverse-reactions.html)
- [Immunize.org: Medical Management of Vaccine Reactions in Children and Teens in a Community Setting \(www.immunize.org/wp-content/uploads/catg.d/p3082a.pdf\)](https://www.immunize.org/wp-content/uploads/catg.d/p3082a.pdf)
- [Immunize.org: Medical Management of Vaccine Reactions in Adults in a Community Setting \(www.immunize.org/wp-content/uploads/catg.d/p3082.pdf\)](https://www.immunize.org/wp-content/uploads/catg.d/p3082.pdf)

Provide Vaccine Information Statements (VIS)

Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide non-English speaking patients with a copy of the VIS in their preferred language, if one is available.

2026-27 COVID-19 VACCINE ADMINISTRATION PROTOCOL/STANDING ORDER FOR PHARMACISTS

- [Immunize.org: COVID-19 Vaccine VIS \(www.immunize.org/vaccines/vis/covid-19/\)](https://www.immunize.org/vaccines/vis/covid-19/)

Report adverse events to VAERS

Report all adverse events following the administration of COVID-19 vaccine to the federal Vaccine Adverse Event Reporting System (VAERS).

- [VAERS: Report an Adverse Event \(https://vaers.hhs.gov/reportevent.html\)](https://vaers.hhs.gov/reportevent.html)

Record keeping and documentation

- Qualified health professionals that are using this document must keep a copy of it on site at all locations administering vaccines pursuant to this protocol/standing order.
- Document each patient's vaccine administration information in the Minnesota Immunization Information Connection (MIIC).

Insurance and billing

This protocol/standing order does not guarantee insurance coverage of the COVID-19 vaccine. Coverage for the COVID-19 vaccine is dependent upon and may vary based on insurance policies and individual plans.

Name of prescriber: Dr. Ruth Lynfield MD, State Epidemiologist and Medical Director, Minnesota Department of Health

License No.: 40312

NPI No.: 1285960302

Prescriber signature: 

Date: September 17, 2026

Ingredient list

- 2026-27 Pfizer-BioNTech COVID-19 vaccine for persons 5 years of age and older: [Package Insert and Patient Package Insert - COMIRNATY \(www.fda.gov/media/151707/download?attachment\)](https://www.fda.gov/media/151707/download?attachment)
- 2026-27 Moderna Spikevax COVID-19 vaccine for persons 6 months of age and older: [Package Insert - SPIKEVAX \(https://www.fda.gov/media/155675/download?attachment\)](https://www.fda.gov/media/155675/download?attachment)
- 2026-27 Moderna mNEXSPIKE COVID-19 vaccine for persons 12 years of age and older: [Package Insert - MNEXSPIKE \(https://www.fda.gov/media/186738/download?attachment\)](https://www.fda.gov/media/186738/download?attachment)
- 2026-27 Novavax Nuvaxovid COVID-19 vaccine for persons 12 years of age and older: [Package Insert and Patient Package Insert - NUVAXOVID \(www.fda.gov/media/186544/download?attachment\)](https://www.fda.gov/media/186544/download?attachment)